Viskase Holdings Details Post-Merger Board, Executive Changes, and 93.7% Icahn Ownership in Amended 10-K

summarizeSummary

Viskase Holdings, Inc. filed an amended 10-K detailing its post-merger board and executive changes, including new CEO and CFO appointments, and confirming Carl Icahn's 93.7% beneficial ownership.

check_boxKey Events

• Post-Merger Corporate Structure Confirmed

  The filing completes the annual report for the fiscal year ended December 31, 2025, following the merger of Enzon Pharmaceuticals, Inc. with Viskase Companies, Inc. on March 26, 2026, and a 1-for-100 reverse stock split on March 24, 2026. The company is now officially Viskase Holdings, Inc.

• Significant Board and Executive Leadership Changes

  Multiple directors and executive officers resigned post-merger, including former CEO/CFO Richard L. Feinstein and Chairman Randolph C. Read. Thomas D. Davis was appointed Chief Executive Officer and Michael Blecic was appointed Chief Financial Officer.

• Carl Icahn and Affiliates Hold 93.7% Ownership

  Carl C. Icahn and affiliated entities now beneficially own approximately 93.7% of Viskase Holdings, Inc.'s common stock as of April 29, 2026, establishing dominant control.

auto_awesomeAnalysis

This amended annual report provides crucial details regarding Viskase Holdings, Inc.'s corporate structure and control following its merger with Viskase Companies, Inc. and a 1-for-100 reverse stock split in March 2026. The filing confirms a significant overhaul of the board of directors and executive leadership, including the appointment of Thomas D. Davis as CEO and Michael Blecic as CFO. Critically, it reveals that Carl C. Icahn and affiliated entities now beneficially own approximately 93.7% of the company's common stock, solidifying his control over the newly formed entity. This information is vital for investors to understand the new governance and ownership landscape of the company.